IJMM International Journal of Molecular Medicine 1107-3756 1791-244X D.A. Spandidos 10.3892/ijmm.2021.4916 ijmm-47-05-04916 Articles Critical role of mass spectrometry proteomics in tear biomarker discovery for multifactorial ocular diseases (Review) MaJessica Yuen Wuen1* SzeYing Hon1* BianJing Fang1 LamThomas Chuen12 Laboratory of Experimental Optometry, Centre for Myopia Research, School of Optometry, The Hong Kong Polytechnic University, Kowloon, P.R. China Centre for Eye and Vision Research, Hong Kong, SAR, P.R. China Correspondence to: Dr Thomas Chuen Lam, Laboratory of Experimental Optometry, Centre for Myopia Research, School of Optometry, The Hong Kong Polytechnic University, 6 Yuk Choi Road, Kowloon, Hong Kong, SAR, P.R. China, E-mail: thomas.c.lam@polyu.edu.hk

Contributed equally

 5 2021 18 03 2021 47 5 83 07 04 2020 14 01 2021 Copyright: © Ma et al. 2021 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The tear film is a layer of body fluid that maintains the homeostasis of the ocular surface. The superior accessibility of tears and the presence of a high concentration of functional proteins make tears a potential medium for the discovery of non-invasive biomarkers in ocular diseases. Recent advances in mass spectrometry (MS) have enabled determination of an in-depth proteome profile, improved sensitivity, faster acquisition speed, proven variety of acquisition methods, and identification of disease biomarkers previously lacking in the field of ophthalmology. The use of MS allows efficient discovery of tear proteins, generation of reproducible results, and, more importantly, determines changes of protein quantity and post-translation modifications in microliter samples. The present review compared techniques for tear collection, sample preparation, and acquisition applied for the discovery of tear protein markers in normal subjects and multifactorial conditions, including dry eye syndrome, diabetic retinopathy, thyroid eye disease and primary open-angle glaucoma, which require an early diagnosis for treatment. It also summarized the contribution of MS to early discovery by means of disease-related protein markers in tear fluid and the potential for transformation of the tear MS-based proteome to antibody-based assay for future clinical application.

 tears dry eye syndrome diabetic retinopathy thyroid eye disease glaucoma biomarker mass spectrometry The Hong Kong Polytechnic University RKTA This work was supported by a Ph.D. student scholarship (grant no. RKTA) of The Hong Kong Polytechnic University. 1. Introduction

The tear film is a thin layer of body fluid secreted and produced by the meibomian gland, the main and accessory lacrimal glands, as well as the goblet cells in the conjunctiva (1). Tear fluid serves several functions: i) Lubricating the ocular surface; ii) providing nutrients to the corneal epithelium; iii) providing a moist and smooth surface for good vision; and iv) protecting the eyes against pathogens (2). The tear film is comprised of three layers: i) The lipid layer; ii) the aqueous layer; and ii) the innermost mucin layer with the aqueous and mucin layers forming a homogeneous layer (3,4). Altogether, it consists of proteins (including enzymes), metabolites, electrolytes, lipids and glucose, and serves a critical function in the ocular system (5). The total tear protein concentration ranges from 3.5 to 9.5 mg/ml in basal tears and reflex tears, but is higher in newborns, ranging from 11 to 13 mg/ml (6), and is increased in closed eye conditions (6 to 18 mg/ml) (7). It has been demonstrated that the proteins in the tear fluid play a significant role in regulating inflammatory responses (8), wound healing (9) and antibacterial protection (10). Mass spectrometry (MS) proteomic analysis not only provides a comprehensive characterization of tear fluid efficiently, but the multiplex nature of acquisition may also provide insights into the key mediators of biological responses and the status of the ocular surface (11). The high concentration of proteins and easy accessibility of tear fluid, compared with other ocular fluids, have made tears a sought-after target for proteomic studies in ophthalmology (12). However, the presence of abundant proteins, including lactotransferrin (LTF), secretory IgA, lipocalin-1 (LCN1) and lysozyme C (LYZ) detected using electrophoresis techniques (13,14) and the small volume of tears has hampered comprehensive protein analysis of low abundant proteins. The advancement in nano-scale liquid chromatography coupled MS (nanoLC-MS) that offers extended dynamic range and sensitivity to identify >1,000 proteins, has opened up the possibility of tear biomarker research (15). With continued advances in techniques from sample preparation to MS acquisition, it is anticipated that the tear fluid will serve as an important matrix to develop molecular assays for ocular diseases and ophthalmology overall using the MS approach. Quantitative profiling and targeted MS methods have allowed multiplexed, reproducible screening of hundreds to thousands of proteins in a single, microliter volume (16) of tear fluid samples in early discovery, clinical trials and clinical proteomics application for the discovery of multifactorial ocular diseases.

 2. Collection of tear fluid for clinical proteomics

Tear fluid can be obtained using several established collection methods, yet different sampling methods are known to affect the quality of tears samples and, consequently, the results of tear proteome analysis (17). The three most commonly adopted sampling methods for tear fluid are cellulose sponges, Schirmer's strips and capillary tubes. These sampling methods are non-invasive and do not require local anesthesia.

Cellulose sponges

A cellulose sponge may be used for tear collection by placing it into the lower conjunctival sac for ~1 min. It has been commonly adopted due to its high effectiveness in collecting tears, even from patients with low tear volume. This method is non-irritating and is generally well-tolerated by patients (18). Additionally, the sponge sampling method enables the standardization of the tear collection volume (19). Nevertheless, a variety of sponges and extraction buffers have been used in different studies, thus making it difficult to directly compare their results (19,20). In addition, some cytokines, including interleukins and g-interferon, bind tightly to the sponge, making the recovery and extraction of these proteins more difficult (21).

 Schirmer's strips

Schirmer's strips are used in the Schirmer's test for dry eye assessment (22). The strip is placed in the inferior conjunctival sac and left in place until it has been wetted to the control line. Later incubation in buffer solution to rehydrate the strip allows proteins or metabolites to be extracted for further molecular tests. This technique yields higher recovery of interleukins compared to samples collected with cellulose sponges (23) and improved protein identification than from tear fluid collected with a capillary tube (24). Although Schirmer's strips have been considered as a convenient and easy to perform method of tear collection, their use can cause strong irritation, leading to reflex tearing that results in unwanted dilution of tears (25). In addition, improper handling can also affect protein content (26). In particular, estimation of the tear protein loss during sample manipulation at the diffusion-based protein extraction stage ranged from 2% (LYZ) to 41.2% (mucin 4) (26).

Both the Schirmer's strip and cellulose sponge methods make use of absorptive materials that have contact with the conjunctiva, which can potentially damage the ocular surface. An increase in the number of certain proteins due to mechanical trauma of the conjunctiva has been reported (27,28). Hence, extra care should be taken to minimize the trauma-induced stimulation of proteins during sample collection.

 Capillary tube

To overcome the aforementioned drawbacks of absorptive materials, capillary tube or pipette sampling can be employed. The tear fluid is drawn from the inferior temporal tear meniscus near the external canthus of the eyes to a disposable borosilicate glass microcapillary tube by simple capillary force (29). Compared with the use of absorptive materials, this method is considered to be less invasive, to avoid reflex tearing, and to result in less protein disruption during the sample recovery process (30). However, it is time-consuming and requires precise handling, and may not be suitable for anxious or uncooperative patients and children (19). Improper handling of capillary tubes can induce reflex tears due to contact between the tube and the conjunctiva. In general, capillary tubes sampling is not always practicable and feasible in clinical studies that require reproducible data from large cohorts, particularly when children are involved (19). Furthermore, the collectible sample volume is limited. To overcome the limited tear volume of samples, pooling of tears from multiple subjects can be useful in research, but is undesirable in clinical studies as individual characteristics cannot be determined (31).

In brief, it is important to select the appropriate collection method for each specific study. For example, when a large sample volume is required, Schirmer's strips are preferable, but if dry eye patients with low tear menisci are involved, cellulose sponges are preferred (32,33). Notably, the results of proteomics studies using different tear fluid collection methods are not directly comparable, and it is important to consider the potential impact of the collection method on protein concentration and expression.

 3. MS proteomics approaches

Proteins are the key functional entities in the cell and arguably form the principle level of information required to understand any cellular function (34). Proteome refers to the entire protein complement expressed by the genome, while proteomics refers to the global analysis of protein mixtures (or their polypeptide components). Protein research and proteomics continue to develop and have become increasingly sophisticated. Proteomics research was initially qualitative, i.e., proteins were identified as being present in samples, providing the foundation for future research, but this alone was insufficient to characterize induced protein regulations and pathological conditions. For these purposes, proteomics analysis needed to be quantitative (35). Consequently, proteomic platforms with quantitative measurement of protein expression and protein post-translational modifications (PTMs) have been developed and become an integral and indispensable part of current proteomic studies (36). Discovery-based proteomics is typically conducted with a comparatively small set of samples to identify and quantify the differential expression of proteins. These proteins can then be verified and validated with a larger sample cohort to better account for biological variation, specificity and clinical longitudinal changes in expression. Data-dependent acquisition (DDA) was the first approach developed to survey abundant peptide masses in an unknown mixture, in which precursors were isolated and fragmented to generate a unique fingerprint spectrum of amino acid sequences for peptide identification in a high-resolution mass spectrometer. However, DDA has poor quantitative performance, because of the bias towards redundant proteins and poor reproducibility of signals and coverage of low abundant proteins (37). Data-independent acquisition (DIA) utilizes software-controlled mass isolation windows across the chromatogram, providing superior reproducibility and consistent acquisition ideal for quantitative results (38). In particular, the Sequential Window Acquisition of All Theoretical Mass Spectra (SWATH-MS) extended the data analysis concept of a targeted approach to achieve high-throughput DIA data extraction and statistical validation. SWATH-MS is one of the first methods to record all fragment ions of the detectable peptide precursors and highly multiplexed fragment ion maps included with low abundant peptides (39). DIA method, which relies on a high-quality mass spectral library generated from the DDA approach for peptide identification, remains the only label-free quantification method to survey and quantify the hundreds of thousands of proteins in complex biological samples without the prior knowledge of fragment mass transitions and peptide occurrences in the sample. Advances in proteomics were required and went hand in hand with intensive progress in computational interfaces, including databases, data processing algorithms, decoy peptides, accurate protein identification and data analysis of large proteome datasets (40). Isobaric tags for relative and absolute quantitation (iTRAQ) and Tandem mass tag (TMT) are isobaric labeling methods used in quantitative proteomics. These methods are based on the covalent labeling of the peptide with designated tags of reporter mass. Peptide samples are labeled and then pooled for preparation. This labeled approach allows multiplexed sampling and quantification of peptides that are ideal for pilot studies, as demonstrated in the analysis of tears in dry eye disease to quantify differential expressed proteins in a single MS acquisition (41).

Phosphorylation and glycosylation are common PTMs of proteins. A pilot study of phosphorylation enrichment using a titanium dioxide (TiO2) column identified a total of 13 phosphoproteins in tear fluid, including mammaglobin-B (SCGB2A1), clusterin and protein UNQ773. Of note, phosphoproteins LCN1, immunoglobulin k constant (IGKC), polymeric immunoglobulin receptor (PIGR), lacritin (LACRT), cystatin S (CST4), proline-rich protein 4 (PRR4), deleted in malignant brain tumors 1 protein (DMBT1), immunoglobulin heavy constant a 1 (IGHA1), LYZ and immunoglobulin J chain (IGJ) had differentially expressed protein levels in ocular diseases, as described in a previously mentioned study (42). The use of PTMs as a biomarker in ocular diseases is limited, despite the high abundance of phosphoproteins reported in tear fluid (43). For example, glycosylation in the proline-rich protein family, and LACRT can be identified without an enrichment procedure (37). Methylation and acylation were observed in LCN1 and LYZ, however there was statistically significant difference of PTMs in dry eye disease (44). A total of 50 N-linked glycans were identified in tears, five low abundance N-glycans (m/z 864.4, 945.5, 994.9, 1039.0 and 1112.0) and one O-glycan (m/z 665.2) were significantly different in patients with diabetes or diabetic retinopathy (45).

 4. Protein sample preparation for MS

One-dimensional and two-dimensional gel electrophoreses (1DGE and 2DGE, respectively) were early proteomic tools used to separate, visualize and determine the size of proteins (46). MS was used to identify spots of abundant proteins and relative quantification of proteins. With this technique, proteins are separated according to isoelectric points (pI) through isoelectric focusing (IEF). In 1974, LTF and LYZ were found to be the major protein constituents in tear fluid (47). Using 1DGE, scientists found serum albumin (ALB) and transferrin were significantly elevated in the tear fluid of eyes even in mild cases of acute catarrhal conjunctivitis (48). Using 2DGE, scientists found lower abundance of proteins in human reflex tears, including CST4, cystatin SN and α-2-glycoprotein, in addition to the previously reported LTF and LYZ (49), in particular, high expression of PRR4 in reflex tears (50). The fluorescence visualization of proteins in GE improved sensitivity compared with traditional Coomassie brilliant blue staining (51). However, irrespective of the staining method used, GE has a limited resolution of complex protein mixtures, low abundance proteins and co-appearing protein isoforms. It is also incompatible with hydrophobic proteins, for which it has limited access to various protein classes (52). Additionally, its limited dynamic range has hampered proteomic analysis of biofluids, such as human plasma, in which protein concentrations can differ up to 12 orders of magnitude (53). Unicellular organisms were used to benchmark 2DGE. However, detection of low abundance proteins remained a problem in this paradigm, despite the use of extended separation range and increased sample load, only 193 proteins were identified. This has demonstrated the limitations of the technique in a relatively simple model, and led to the conclusion that GE is not suitable for comprehensive global protein detection and quantitative profiling of protein networks (54). One-dimensional-liquid chromatography (1D-LC) offered a solution to the limitations of GE and has become increasingly popular over the past decade. Compared with GE-based proteomics, LC-based proteomics have improved reproducibility, streamlined peptide separation, increased sample throughput and dynamic range, and reduced sample consumption (55). These advances enabled the characterization of proteins in tissues (56), cells (57), plasma (58) and tears (59). The separation efficiency of LC is dependent on peak capacity, i.e., the maximum number of proteins that can be resolved in each separation time in a single sample acquisition (60). In human plasma, which has a particularly complex protein content, the highest achievable peak capacity of LC was reported to be 1,500 (61). It was also reported that the theoretical peak capacity of GE is three times lower than LC methods, due to its confined and definite retention volume (62). Consequentially, MS-based targeted proteomics have been rapidly adopted for quantifying proteins in complex clinical samples (63,64). MS-based approaches perform particularly well with respect to assay sensitivity and specificity, when testing biomarker panels, rather than individual markers. Therefore, this technology has paved the way for multiparametric diagnostics that can significantly increase diagnostic accuracy (65). Currently, the only Food and Drug Administration (FDA)-approved, multi-parametric clinical test is designed to aid in the diagnosis of ovarian cancer. This test, which uses five serum proteins [CA125, transthyretin, apolipoprotein A-I, β2-microglobulin (B2M) and transferrin], correctly predicted ovarian cancer in 94% of cases, which was significantly improved compared with the 66% rate observed with a single-parametric assay based on CA125 alone (66,67). Therefore, MS-based proteomics is likely to become an important tool in the identification and application of multi-analyte biomarker panels, including the use of tear fluid samples for the diagnosis of ophthalmic diseases and conditions.

 5. Normal tear proteome in healthy ocular condition

Under normal healthy ocular conditions, tear proteins are mainly released from the lacrimal gland (68), meibomian glands (69), goblet cells (70), and accessory lacrimal glands. Early discovery studies identified only 54 proteins in tears from subjects without eye diseases (37). The number of proteins identified increased notably to 491 in closed-eye tear fluid using hybrid linear ion trap-Fourier transform (LTQ-FT) and LTQ-Orbitrap mass spectrometers (71). The majority of the identified proteins were involved in the modulation of the immune system. They were responsible for carrying out immune, inflammatory responses as well as defense responses to pathogens. This study also focused on the identification of proteases and antioxidant enzymes. Among the 491 proteins identified, 64 were proteases or protease inhibitors, and 18 were antioxidant enzymes. These findings could explain the importance of tears in protecting the healthy ocular surface from noxious external stimulants and irritants. The results of studies of the proteome of human tears in healthy subjects are shown in Table I.

Tear proteome profiles of normal subjects have been the basic research standard for method assessment and development of the clinical use of tear proteomics. LTF, SCGB2A1, haptoglobin, α-1-antitrypsin (SERPINA1), CST4, LCN1 and LACRT were found to be significantly upregulated in the tear fluid of female patients compared with male patients. A total of 253 proteins and 231 proteins were identified in the tears of male and female patients, respectively, using an electrophoresis method (72). The regulation of LCN1 in tear fluid was shown to be hormone-dependent in an experimental rabbit model, but the function of LCN1 in the tears of female patients remains unknown (73). Most upregulated proteins in the tear fluid of female patients were responsible for local immune defense responses. In-depth analysis with the use of fractionation, nanoscale reversed phase-liquid chromatography (nanoRP-LC), and TripleTOF 5600 MS resulted in the report of a comprehensive human tear proteome, comprising the discovery of 1,543 proteins in normal healthy subjects (15). This number of proteins was significantly higher than other reports, so it should be noted that isoforms of the same protein were counted as separate proteins and only 714 proteins of the reported proteins were repeatable and reproducible in the triplicate analysis. Another study reported a total of 747 proteins in human tears (74), of which 595 were also reported by Zhou et al (15). Using an optimized extraction method and two-dimensional strong cation exchange-reversed phase (SCX-RP) with greater orthogonality of separation, Aass et al (75) reported 1,526 proteins in tear-fluid. We have converted the International Protein Index (IPI), GenInfo Identifier (GI) protein identification from the literature listed in Table I to a matched UniProt reviewed proteome for comparison. A total of 3,724 unique proteins (1% False Discovery Rate in each study) were identified in tear fluid, with 1,397 (60%) unique proteins only identified in Schirmer's strip samples, and 60 (3%) unique proteins in tear samples collected with a capillary tube (Fig. 1). These independent studies had reported the most tear protein analyzed with LTQ-Orbitrap (Thermo Fisher Scientific, Inc.) and TripleTOF 5600 mass spectrometers (SCIEX). The combination of these studies is likely to increase the confidence of such protein identification. We propose that 435 (19%) proteins commonly reported can be identified regardless of the tear fluid collection method and are the higher abundant, core protein in the composition of tear fluid. Comprehensive information of these 435 common proteins was derived from the UniProt database (https://www.uniprot.org) and is summarized in Table SI. Gene Ontology information on their biological processes and protein class was analyzed using the Omicsbean classification system (http://www.omicsbean.cn). The reported genes are categorized into 'Biological Process', 'Cell Component' and 'Molecular Function', and it was found that the enriched genes were involved in the top three pathways associated with 'vesicle-mediated transport', 'immune effector process' and 'exocytosis' (Fig. 2). These data were generated from a mixture of MS and vendors. Regardless of the MS system, common proteins are likely to be identified in tear fluid, but this will depend on the collection method. Several reports have stated that Orbitrap MS yields higher protein identifications compared with the TripleTOF MS (76-79).

 6. Putative protein markers in tear fluid Dry eye disease

Based on the definition and classification provided by the International Dry Eye Workshop in 2017 (80), dry eye disease is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film that leads to tear film instability and hyperosmolarity, ocular surface inflammation, and neurosensory abnormalities and associated ocular symptoms (81). The two common types of dry eyes are known as the aqueous-deficient and evaporative dry eyes (82). Clinical diagnosis of dry eye diseases is based on questionnaires, Schirmer test, phenol red thread test, tear breakup time, corneal staining and tear osmolarity (83,84). However, these assessments have shown poor reproducibility and large inter-test variability, as well as a poor correlation between the findings and subjective symptoms (85). Hence, an unmet need requires a reliable prognostic method when diagnosing dry eye diseases. Proteomic analysis of tear fluid has been increasingly used to identify biomarkers for ocular diseases.

Ocular surface inflammation is one of the major findings of patients with dry eye so several inflammatory proteins can act as possible biomarkers of dry eyes (86). It is reported that several inflammatory proteins are reported to be differentially expressed, including upregulated proteins of α-enolase (ENO1), α-1-acid glycoprotein 1 (ORM1), calgranulin A (S100A8), calgranulin B (S100A9), calvasculin (S100A4) and calgizzarin, and downregulated proteins of prolactin-inducible protein, LTF, LCN1 and LYZ (87). ORM1 protein promotes anti-inflammatory responses, whereas S100A8 and S100A9 proteins are pro-inflammatory proteins and are commonly found in the area of inflammation (88). Downregulated proteins LTF, LYZ and LCN1 are abundant proteins that protect against pathogens in tear fluid. The decreased expression of these proteins may explain why patients are prone to infectious ocular surface diseases (89). Notably, lipocalins promote the formation and maintenance of a compact and homogeneous outermost lipid layer of the tear film (90). Hence, decreased levels of lipocalins may lead to an unstable lipid layer, as well as an increased evaporation rate of the tear fluid. The levels of S100A8 and S100A9 are associated with the severity of meibomian gland dysfunction (MGD) and with symptoms of ocular redness and transient blurring in patients with dry eye (91). The upregulation of S100A8 and S100A9 occurs in response to the oxidative changes in redox regulation and inflammatory regulation (92). Significantly upregulated levels of ALB and downregulated lactase-phlorizin hydrolase, LCN1, SCGB2A1, and lipophilin A were reported in the evaporative dry eye disease (93). The increased level of ALB is an indication of passive exudation, i.e. a leaky blood-eye barrier in conjunctival vessels (94).

Another previous study reported the differential expression of PRR4, zymogen granule protein 16 homolog B (ZG16B), DMBT1, LACRT, opiorphin prepropeptide (PROL1), aldehyde dehydrogenase dimeric NADP-preferring (ALDH3A1), phosphatidylethanolamine-binding protein 1, serotransferrin (TF), together with S100A8, S100A9, SCGB2A1, ENO1 and ORM1 that were previously reported in the literature (95). The increased expression of PRR4 and ZG16B in dry eye disease may indicate an impaired neurological process of the lacrimal gland. Downregulation of DMBT1 impairs epithelial differentiation and cellular defense mechanisms, whereas the reduction of LACRT may account for the reduced tears secretion in patients with dry eye (96). The reduction of PROL1 affects the paracrine or autocrine pathway of the lacrimal system (97). The ALDH3A1 protein protects against the oxidative stress of toxic radicals on the corneal surface (98). The upregulation of TF protein was only identified in the aqueous deficient type of dry eye (95). A previous study demonstrated the complex molecular difference between dry eye disease and MGD. Thioredoxin, Ig γ-1, membrane-associated phospholipase A2, SERPINA1 and antileukoproteinase (SLPI) were found to be upregulated in patients with dry eye, yet these proteins were downregulated in MGD. In addition, lactoperoxidase (LPO) was significantly downregulated in dry eye disease and upregulated in MGD (99). The upregulation of these proteins suggests enhanced immune, host-defense and proteolytic responses in aqueous-deficient dry eye disease, whereas the contrary may be the case in the evaporative dry eye caused by MGD. Furthermore, the higher level of hyperosmolarity in patients with MGD may lead to an increased expression of oxidative stress-associated LPO protein in MGD when compared with patients with dry eye. The differential expression of proteins between MGD and dry eye suggest different regulatory processes. S100A8, S100A9 and ORM1 were identified as differentially expressed in all the dry eye studies reported in the present review (Table II). Hence, these proteins may serve as biomarkers of dry eye disease, in addition to the established biomarker matrix metalloproteinase-9 (MMP-9) that is already being employed in the diagnosis of dry eye disease (100). Although anterior ocular inflammation is a typical feature of Sjögren syndrome, it is considered to be a systemic autoimmune disease with some distinct clinical presentation (101). Different from physiological dry eyes, aqueous-deficient and evaporative dry eyes, which could be clinically difficult to differentiate using routine clinical assessments. It was recently found that the elevated MMP-9 protein biomarker is non-specific and difficult to distinguish Sjögren syndrome from typical dry eye diseases (102). MS-based proteomics approaches enabled the discovery of the upregulation of other pro-inflammatory proteins, including LIM domain only protein 7, E3 ubiquitin-protein ligase and Copine-1, as well as in the involvement of TNF-α signaling (103,104), which suggested the possibility that specific molecular biomarkers may be developed for more specific clinical diagnosis.

These studies have provided preliminary data on protein biomarkers in tear fluid using MS techniques. However, there are several limitations of using tear proteomics to make a diagnosis of dry eyes. The tear sampling methods and ways of sample manipulation differ among the reported studies; hence, a direct comparison between these studies may not be appropriate. To achieve comparable results, standardization of sampling methods and sample manipulation protocols are required in the future. Additionally, S100A8 and S100A9, which were differentially expressed in all of the studies, were also reported in patients with glaucoma (Table II), indicating that these inflammatory proteins are not differentially expressed uniquely in patients with dry eye (105). In summary, several potential biomarkers have been identified in patients with dry eyes, but whether a diagnosis of dry eyes can be based on tear proteomics remains to be determined and defined. A signature panel of tear fluid biomarkers is needed to address overlap with other conditions to increase the specificity of tear fluid protein markers for the diagnosis of dry eye diseases.

 Diabetic retinopathy

Diabetic retinopathy is a common complication of diabetes mellitus (DM). The condition is asymptomatic in the early stages of disease development, yet it can cause irreversible blindness in its final stages. Tear composition can be affected by DM, although the tear film is not in direct contact with the retina (106). Hence, tear proteins may act as biomarkers for the screening of diabetic retinopathy. The relative abundance of LACRT, Ig lambda chain C region (LAC), LTF, LYZ, LCN1 and SCGB2A1 proteins were upregulated in patients with proliferative diabetic retinopathy (PDR) compared with non-PDR and healthy subjects (107). The upregulated expression levels of LTF, LAC and LACRT may reflect an increased inflammatory response, potentially caused by macular edema, vascular abnormalities, the proliferation of the ocular cells, and an indicator of the pro-proliferative environment that is essential for the progression of diabetic retinopathy (108).

 Thyroid eye disease

Thyroid-associated orbitopathy (TAO) is an autoimmune disorder that affects the orbit. TAO is characterized by enlarged extraocular muscles, orbital tissue and inflammatory changes, including upper eyelid retraction, proptosis and erythema of the conjunctiva (109). There are two phases of TAO: The inflammatory phase, which requires anti-inflammatory treatment, and a later less active stage (110). The clinical diagnosis, assessment and management of the disease are based on the Clinical Activity Score (CAS) (111). However, disease onset, prognosis and time course of TAO remain unclear. TAO mainly affects the extraocular muscles, eyelid and orbital tissue. These surrounding damaged tissues may release different proteins into tears or by passive transport from blood; therefore, tears may contain potential protein markers for the diagnosis of TAO (112). However, the composition of tears collected from patients with TAO need to be analyzed carefully as it may contain certain inflammatory proteins that are associated with exposure keratitis, which is a common complication of TAO (113).

In one previous study, the expression of three proteins was modulated in patients with TAO (114). LYZ was found to be upregulated, whereas PRP4 and B2M were downregulated in patients with TAO. LYZ is a proteolytic protein that is important in the immune response (115) and increased LYZ is found in patients with autoimmune diseases (116). The increase of LYZ may suggest increased inflammatory responses of the lacrimal gland. Lacrimal PRP4 can regulate the microflora of the eye to protect the ocular surface (117). The inflammatory processes of the orbit in TAO may decrease the lacrimal expression of PRP4. It has been demonstrated that increased levels of inflammation and higher CAS values are associated with lower levels of PRP4, indicating the progressive nature of the inflammatory lacrimal gland dysfunction in patients with TAO (114). B2M belongs to the major histocompatibility complex class I molecules and also plays an important role in immune responses (118). The downregulation of B2M may reflect altered immune function in this auto-immune disease.

Patients with TAO can have signs and symptoms similar to dry eye syndrome, which can result in delayed diagnosis of TAO (117). In comparison to normal subjects, transcription activator BRG1 (SMCA4), PROL1, PPR4 and S100A8 proteins were downregulated, whereas midasin, POTE ankyrin domain family member I and LYZ proteins were upregulated in patients with TAO (117). In comparison to patients with dry eye, UDP-glucose 6-dehydrogenase (UGDH), annexin A1, cystatin-C (CST3), heat shock protein β1 (HSPB1), galectin-1, PROL1, S100A8 and SMCA4 proteins were downregulated in patients with TAO (117). The apoptosis of lacrimal cells can cause the downregulation of PROL1 and PRR4 proteins, the protective enzymes secreted by the lacrimal acinar cells in TAO (119). The damage to the lacrimal cells can reduce the number of cystatin proteins, which perform protective function in the tears (120). UGDH protein is responsible for the indirect production of the glycosaminoglycans that are expressed in fibroblasts in the active phase of TAO (121). The downregulation of UGDH protein can be explained by the fact that the majority of the patients involved in this study were in advanced and inactive stages of TAO. A similar study reported 12 upregulated proteins in patients with TAO, including caspase-14, SLPI, dermcidin (DCD), procollagen-lysine 2-oxoglutarate 5-dioxygenase 2, mesothelin, apolipoprotein D, glutathione peroxidase 3, zinc-α-2-glycoprotein 1, DMBT1, ZG16B and LACRT (122). The overexpression of CASP14, SLPI and LYZ proteins may represent the inflammatory responses of the ocular surface, orbital tissue or lacrimal gland. However, the exact function of CASP14 in tear fluid remains unclear. DCD protein has anti-microbial properties and has been detected in conjunctival cells (123). Increased amounts of DCD protein suggest more bulbar conjunctiva inflammation in patients with TAO (124). In a more recent study, retinal dehydrogenase 1, SERPINA3 and CST3 proteins were found to be upregulated in tear fluid obtained from patients with TAO (125). CST3 protein is a cysteine protease inhibitor that is concentrated and expressed in the retinal pigment epithelium (126). The concentration of CST3 protein in the blood is associated with thyroid functioning (127). The downregulation of retinol dehydrogenase 11 protein may result in reduced synthesis of retinoic acid, hence, affecting the visual pigment and leading to vision loss (128). Increased expression of SERPINA3, a protein responsible for mediating inflammatory responses, may reflect the increased level of eye inflammation in TAO, which is an autoimmune disease with orbital inflammatory responses. Different biomarkers for TAO have been identified across different studies (Table II), further validation should be carried out to confirm potential biomarkers and these biomarkers should be analyzed according to the severity or different stages of TAO.

 Primary open-angle glaucoma (POAG)

Glaucoma is a progressive neurodegenerative disease that causes optic nerve head damage, retinal nerve fiber layer defects, and is associated with the loss of the visual field (129). It is one of the main causes of blindness worldwide (130). The underlying mechanism of glaucoma remains unclear, and the clinical diagnosis of glaucoma relies on several assessments, including tonometry, dilated fundus image examination, visual field test, gonioscopy and pachymetry (129). Visual field impairment is a cause of irreversible damage to retinal ganglion cells (131). Tear fluid proteomic profiling may provide novel insights into the understanding and diagnosis of glaucoma and may serve to monitor therapy, including the side effects of medication. POAG is the most common subtype of open-angle glaucoma in the European population (132). The damaged trabecular meshwork and modification of the aqueous humor leads to an impaired drainage system. The accumulation of fluid increases the intraocular pressure (IOP) of the eye (133). Pseudoexfoliative glaucoma (PXG) is another subtype of POAG and is characterized by the production and accumulation of abnormally high concentration of fibrillar and proteinaceous substances in the anterior segment of the eyes (134). These substances can block the ocular drainage system and thus increase the IOP of the eye, one of the risk factors of glaucoma (135). A total of 23 differentially expressed proteins have been reported in POAG and PXG. Cystatin-SA, CST4, SCGB2A1, Ig γ-2 chain C region and PRR4 proteins were found to be upregulated in POAG, but not PXG. Peroxiredoxin-1, IGJ, galectin-3, PIGR, keratin type I cytoskeletal 19, S100A4, S100A8 and LACRT were found to be downregulated in POAG compared with PXG samples. More importantly, keratin type I cytoskeletal 10 and apolipoprotein A-II proteins are unique to POAG tear fluid (136). B2M, HSPB1, IGHA1, immunoglobulin heavy constant α2, IGJ, IGKC, LTF, LYZ, PIGR, TF and ALB proteins were also upregulated in patients with POAG (136). The modulation of these proteins between treated and untreated POAG groups indicated that PGA works effectively via the anti-inflammatory mechanism. Proteomics was applied to monitor patients chronically treated with topical antiglaucoma medications, finding that SCGB2A1, S100A8, S100A9 and 14-3-3 ζ/δ proteins were upregulated, whereas PRR4 was downregulated in patients with glaucoma treated with IOP lowering medication (105). The results indicated that the use of topical antiglaucoma medications for >1 year affects the ocular surface by inducing inflammatory responses. The tear fluid proteome of the medically treated patients with glaucoma and patients with dry eyes compared with normal control subjects have shown upregulation of S100A8 and S100A9 proteins in both glaucoma and dry eye patients. Proteins expressed in medically treated glaucoma eyes (SCGB2A1, 14-3-3 ζ/δ, PRR4) or dry eyes (ENO1, S100A4) did not exhibit a common expression pattern between conditions (137). These results suggested that distinct, yet complex mechanisms lead to different inflammatory responses in ocular diseases that can be distinguished using MS-based proteomic techniques.

 7. Conclusions

The present review provided a brief introduction to the development of proteomics platforms for tear proteome studies. The proteome identified in normal tear fluid and its expression in dry eye syndrome, diabetic retinopathy, thyroid eye disease and POAG were summarized. MS-based methods have evolved rapidly with technological advances in high-resolution mass spectrometers and data analysis tools for a variety of discovery-based experiments, resulting in ever-larger proteomic datasets in tear fluid. With respect to accurate quantitative proteomics, DIA and labeled tags offer consistent quantification of proteins in disease conditions for both pilot and large cohort studies. MS technology continues to improve and has enabled in-depth protein profiling, reliable quantification with superior flexibility for assay development, and remains the only anti-body-free approach for protein analysis in biological samples. The consistent results of analyzing the microliter volumes of tear fluid or differentiated proteins has demonstrated the potential development of assays for ocular diseases and ophthalmology overall using a variety of MS approaches. For future approved molecular diagnostics, a custom-made antibody-based assay or point of care diagnostic molecular kit could be developed to target specific proteins, taking full advantage of established, lower-cost, and ease of use into clinical use.

 Supplementary Data Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

JYWM and YHS drafted the manuscript. JFB edited and formatted the manuscript. TCL conceived the idea, proofread the manuscript, and provided financial support. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 Acknowledgments

The authors would like to thank Dr Maureen Boost (Hong Kong Polytechnic University, Hong Kong, China) for her diligent proofreading of the article.

 References DogruMOkadaNAsano-KatoNTanakaMIgarashiATakanoYFukagawaKShimazakiJTsubotaKFujishimaHAtopic ocular surface disease: Implications on tear function and ocular surface mucinsCornea248 SupplS18S23200510.1097/01.ico.0000178741.14212.5316227818 GipsonIKThe ocular surface: The challenge to enable and protect vision: The Friedenwald lectureInvest Ophthalmol Vis Sci4843904398200710.1167/iovs.07-0770178982562886589 MianoFMazzoneMGiannettoAEneaVMc CauleyPBaileyAWinlovePCInterface properties of simplified tear-like fluids in relation to lipid and aqueous layers compositionAdv Exp Med Biol506405417200210.1007/978-1-4615-0717-8_58 King-SmithPEBaileyMDBraunRJFour characteristics and a model of an effective tear film lipid layer (TFLL)Ocul Surf11236245201310.1016/j.jtos.2013.05.003241122274313865 KijlstraAKuizengaAAnalysis and function of the human tear proteinsAdv Exp Med Biol350299308199410.1007/978-1-4615-2417-5_518030492 EsmaeelpourMWattsPOBoultonMECaiJMurphyPJTear film volume and protein analysis in full-term newborn infantsCornea30400404201110.1097/ICO.0b013e3181f22cd9 SackRASatheSBeatonATear turnover and immune and inflammatory processes in the open-eye and closed-eye environments: Relationship to extended wear contact lens useEye Contact Lens29Suppl 1S80S84S192S194200310.1097/00140068-200301001-0002212772738 SternMESchaumburgCSDanaRCalongeMNiederkornJYPflugfelderSCAutoimmunity at the ocular surface: Pathogenesis and regulationMucosal Immunol3425442201010.1038/mi.2010.26204853293577924 SchichtMGarreisFHartjenNBeilekeSJacobiCSahinAHollandDSchröderHHammerCMPaulsenFBräuerLSFTA3-a novel surfactant protein of the ocular surface and its role in corneal wound healing and tear film surface tensionSci Rep89791201810.1038/s41598-018-28005-9 KwongMSEvansDJNiMCowellBAFleiszigSMHuman tear fluid protects against Pseudomonas aeruginosa keratitis in a murine experimental modelInfect Immun7523252332200710.1128/IAI.01404-06173250541865794 ZhouLBeuermanRWThe power of tears: How tear proteomics research could revolutionize the clinicExpert Rev Proteomics14189191201710.1080/14789450.2017.128570328117610 HaganSMartinEEnriquez-de-SalamancaATear fluid biomarkers in ocular and systemic disease: Potential use for predictive, preventive and personalised medicineEPMA J715201610.1186/s13167-016-0065-3274134144942926 GachonAMLacazetteETear lipocalin and the eye's front line of defenceBr J Ophthalmol82453455199810.1136/bjo.82.4.45396402001722558 KuizengaAvan HaeringenNJKijlstraAIdentification of lectin binding proteins in human tearsInvest Ophthalmol Vis Sci323277328419911748557 ZhouLZhaoSZKohSKChenLVazCTanavdeVLiXRBeuermanRWIn-depth analysis of the human tear proteomeJ Proteomics7538773885201210.1016/j.jprot.2012.04.05322634083 MishimaSGassetAKlyceSDJrBaumJLDetermination of tear volume and tear flowInvest Ophthalmol526427619665947945 RentkaAKoroskenyiKHarsfalviJSzekaneczZSzucsGSzodorayPKemeny-BekeAEvaluation of commonly used tear sampling methods and their relevance in subsequent biochemical analysisAnn Clin Biochem54521529201710.1177/000456321769584328193107 EsmaeelpourMCaiJWattsPBoultonMMurphyPJTear sample collection using cellulose acetate absorbent filtersOphthalmic Physiol Opt28577583200810.1111/j.1475-1313.2008.00603.x19076560 Inic-KanadaANussbaumerAMontanaroJBelijSSchlacherSSteinEBintnerNMerioMZlabingerGJBarisani-AsenbauerTComparison of ophthalmic sponges and extraction buffers for quantifying cytokine profiles in tears using Luminex technologyMol Vis18271727252012232337823519369 López-CisternasJCastillo-DiazJTraipe-CastroLLópez-SolisROUse of polyurethane minisponges to collect human tear fluidCornea25312318200610.1097/01.ico.0000183531.25201.0d16633032 RohanLCEdwardsRPKellyLAColenelloKABowmanFPCrowley-NowickPAOptimization of the weck-Cel collection method for quantitation of cytokines in mucosal secretionsClin Diagn Lab Immunol74548200010.1128/CDLI.7.1.45-48.20001061827595820 PosaABräuerLSchichtMGarreisFBeilekeSPaulsenFSchirmer strip vs capillary tube method: Non-invasive methods of obtaining proteins from tear fluidAnn Anat195137142201310.1016/j.aanat.2012.10.00123357333 VanDerMeidKRSuSPKrenzerKLWardKWZhangJZA method to extract cytokines and matrix metalloproteinases from Schirmer strips and analyze using LuminexMol Vis17105610632011215525003086627 NättinenJAapolaUJylhäAVaajanenAUusitaloHComparison of capillary and Schirmer strip tear fluid sampling methods using SWATH-MS proteomics approachTransl Vis Sci Technol916202010.1167/tvst.9.3.16327146427351636 StuchellRNFeldmanJJFarrisRLMandelIDThe effect of collection technique on tear compositionInvest Ophthalmol Vis Sci2537437719846698755 DenisinAKKarnsKHerrAEPost-collection processing of Schirmer strip-collected human tear fluid impacts protein contentAnalyst13750885096201210.1039/c2an35821b22991688 van HaeringenNJGlasiusEThe origin of some enzymes in tear fluid, determined by comparative investigation with two collection methodsExp Eye Res22267272197610.1016/0014-4835(76)90054-31269547 ZhouLBeuermanRWTear analysis in ocular surface diseasesProg Retin Eye Res31527550201210.1016/j.preteyeres.2012.06.00222732126 CastelliSArasiSPawankarRMatricardiPMCollection of nasal secretions and tears and their use in allergologyCurr Opin Allergy Clin Immunol1819201810.1097/ACI.0000000000000412 LeonardiAAllergy and allergic mediators in tearsExp Eye Res117106117201310.1016/j.exer.2013.07.01923891862 Green-ChurchKBNicholsKKKleinholzNMZhangLNicholsJJInvestigation of the human tear film proteome using multiple proteomic approachesMol Vis144564702008183349582268847 KojimaTDogruMKawashimaMNakamuraSTsubotaKAdvances in the diagnosis and treatment of dry eyeProg Retin Eye ResJan292020Epub ahead of print10.1016/j.preteyeres.2020.10084210.1016/j.preteyeres.2020.10084232004729 MainstoneJCBruceASGoldingTRTear meniscus measurement in the diagnosis of dry eyeCurr Eye Res15653661199610.3109/027136896090089068670769 AltelaarAFMunozJHeckAJNext-generation proteomics: Towards an integrative view of proteome dynamicsNat Rev Genet143548201310.1038/nrg3356 SchubertOTRöstHLCollinsBCRosenbergerGAebersoldRQuantitative proteomics: Challenges and opportunities in basic and applied researchNat Protoc1212891294201710.1038/nprot.2017.04028569762 ZhaoYJensenONModification-specific proteomics: Strategies for characterization of post-translational modifications using enrichment techniquesProteomics946324641200910.1002/pmic.200900398197434302892724 LiNWangNZhengJLiuXMLeverOWEricksonPMLiLCharacterization of human tear proteome using multiple proteomic analysis techniquesJ Proteome Res420522061200510.1021/pr050197016335950 GilletLCNavarroPTateSRöstHSelevsekNReiterLBonnerRAebersoldRTargeted data extraction of the MS/MS spectra generated by data-independent acquisition: A new concept for consistent and accurate proteome analysisMol Cell Proteomics11O111.016717201210.1074/mcp.O111.016717222617253433915 CollinsBCHunterCLLiuYSchillingBRosenbergerGBaderSLChanDWGibsonBWGingrasACHeldJMMulti-laboratory assessment of reproducibility, qualitative and quantitative performance of SWATH-mass spectrometryNat Commun8291201710.1038/s41467-017-00249-5288275675566333 MolloyMPThe challenge of industrializing proteomicsNat Biotechnol21597200310.1038/nbt0603-597a12776137 SrinivasanSThangaveluMZhangLGreenKBNicholsKKiTRAQ quantitative proteomics in the analysis of tears in dry eye patientsInvest Ophthalmol Vis Sci5350525059201210.1167/iovs.11-9022227366083410666 ZhaoZLiuJWasingerVCMaloufTNguyen-KhuongTWalshBWillcoxMDTear lipocalin is the predominant phosphoprotein in human tear fluidExp Eye Res90344349201010.1016/j.exer.2009.11.013 YouJFitzgeraldACozziPJZhaoZGrahamPRussellPJWalshBJWillcoxMZhongLWasingerVLiYPost-translation modification of proteins in tearsElectrophoresis3118531861201010.1002/elps.20090075520506419 HuangZDuCXPanXDThe use of in-strip digestion for fast proteomic analysis on tear fluid from dry eye patientsPLoS One13e0200702201810.1371/journal.pone.0200702300749976075744 Nguyen-KhuongTEverest-DassAVKauttoLZhaoZWillcoxMDPackerNHGlycomic characterization of basal tears and changes with diabetes and diabetic retinopathyGlycobiology25269283201510.1093/glycob/cwu108 MagdeldinSEnanySYoshidaYXuBZhangYZureenaZLokamaniIYaoitaEYamamotoTBasics and recent advances of two dimensional-polyacrylamide gel electrophoresisClin Proteomics1116201410.1186/1559-0275-11-16 BroekhuyseRMTear lactoferrin: A bacteriostatic and complexing proteinInvest Ophthalmol1355055419744835007 BertaAA polyacrylamide-gel electrophoretic study of human tear proteinsGraefes Arch Clin Exp Ophthalmol2199599198210.1007/BF021734487141235 MolloyMPBolisSHerbertBROuKTylerMIvan DykDDWillcoxMDGooleyAAWilliamsKLMorrisCAWalshBJEstablishment of the human reflex tear two-dimensional polyacrylamide gel electrophoresis reference map: New proteins of potential diagnostic valueElectrophoresis1828112815199710.1002/elps.1150181516 PerumalNFunkeSWoltersDPfeifferNGrusFHCharacterization of human reflex tear proteome reveals high expression of lacrimal proline-rich protein 4 (PRR4)Proteomics1533703381201510.1002/pmic.20140023926173177 LadnerCLYangJTurnerRJEdwardsRAVisible fluorescent detection of proteins in polyacrylamide gels without stainingAnal Biochem3261320200410.1016/j.ab.2003.10.04714769330 WilliamsJGGratzerWBLimitations of the detergent-polyacrylamide gel electrophoresis method for molecular weight determination of proteinsJ Chromatogr57121125197110.1016/0021-9673(71)80013-44102682 CorthalsGLWasingerVCHochstrasserDFSanchezJCThe dynamic range of protein expression: A challenge for proteomic researchElectrophoresis2111041115200010.1002/(SICI)1522-2683(20000401)21:6<1104::AID-ELPS1104>3.0.CO;2-C10786884 GygiSPCorthalsGLZhangYRochonYAebersoldREvaluation of two-dimensional gel electrophoresis-based proteome analysis technologyProc Natl Acad Sci USA9793909395200010.1073/pnas.1602707971092019816874 ShiYXiangRHorvathCWilkinsJAThe role of liquid chromatography in proteomicsJ Chromatogr A10532736200410.1016/S0021-9673(04)01204-X15543969 UhlénMFagerbergLHallströmBMLindskogCOksvoldPMardinogluASivertssonÅKampfCSjöstedtEAsplundAProteomics. Tissue-based map of the human proteomeScience3471260419201510.1126/science.126041925613900 NagarajNWisniewskiJRGeigerTCoxJKircherMKelsoJPääboSMannMDeep proteome and transcriptome mapping of a human cancer cell lineMol Syst Biol7548201110.1038/msb.2011.81220683313261714 GeyerPEKulakNAPichlerGHoldtLMTeupserDMannMPlasma proteome profiling to assess human health and diseaseCell Syst2185195201610.1016/j.cels.2016.02.01527135364 NättinenJJylhäAAapolaUMäkinenPBeuermanRPietiläJVaajanenAUusitaloHAge-associated changes in human tear proteomeClin Proteomics1611201910.1186/s12014-019-9233-5309762096441198 GilarMNeueUDPeak capacity in gradient reversed-phase liquid chromatography of biopolymers. Theoretical and practical implications for the separation of oligonucleotidesJ Chromatogr A1169139150200710.1016/j.chroma.2007.09.00517897658 ShenYZhaoRBelovMEConradsTPAndersonGATangKPasa-TolićLVeenstraTDLiptonMSUdsethHRSmithRDPacked capillary reversed-phase liquid chromatography with high-performance electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry for proteomicsAnal Chem7317661775200110.1021/ac001133611338590 HsiehEJBeremanMSDurandSValaskovicGAMacCossMJEffects of column and gradient lengths on peak capacity and peptide identification in nanoflow LC-MS/MS of complex proteomic samplesJ Am Soc Mass Spectrom24148153201310.1007/s13361-012-0508-63554873 DoerrAMass spectrometry-based targeted proteomicsNat Methods1023201310.1038/nmeth.228623547294 CarapitoCAebersoldRTargeted proteomicsProteomics121073201210.1002/pmic.20127003522577009 BorrebaeckCAPrecision diagnostics: Moving towards protein biomarker signatures of clinical utility in cancerNat Rev Cancer17199204201710.1038/nrc.2016.15328154374 ZhangZAn in vitro diagnostic multivariate index assay (IVDMIA) for ovarian cancer: Harvesting the power of multiple biomarkersRev Obstet Gynecol535412012225821253349922 UelandFRDesimoneCPSeamonLGMillerRAGoodrichSPodzielinskiISokollLSmithAvan NagellJRJrZhangZEffectiveness of a multivariate index assay in the preoperative assessment of ovarian tumorsObstet Gynecol11712891297201110.1097/AOG.0b013e31821b511821606739 JanssenPTvan BijsterveldOPOrigin and biosynthesis of human tear fluid proteinsInvest Ophthalmol Vis Sci2462363019836841010 TsaiPSEvansJEGreenKMSullivanRMSchaumbergDARichardsSMDanaMRSullivanDAProteomic analysis of human meibomian gland secretionsBr J Ophthalmol90372377200610.1136/bjo.2005.080846164889651856970 GipsonIKGoblet cells of the conjunctiva: A review of recent findingsProg Retin Eye Res544963201610.1016/j.preteyeres.2016.04.005270913234992623 de SouzaGAGodoyLMMannMIdentification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitorsGenome Biol7R72200610.1186/gb-2006-7-8-r72169013381779605 AnanthiSSanthoshRSNilaMVPrajnaNVLalithaPDharmalingamKComparative proteomics of human male and female tears by two-dimensional electrophoresisExp Eye Res92454463201110.1016/j.exer.2011.03.00221396361 SeamonVVellalaKZylberbergCPonamarevaOAzzaroloAMSex hormone regulation of tear lipocalin in the rabbit lacrimal glandExp Eye Res87184190200810.1016/j.exer.2008.05.01218653183 TongLZhouXYJylhaAAapolaULiuDNKohSKTianDQuahJUusitaloHBeuermanRWZhouLQuantitation of 47 human tear proteins using high resolution multiple reaction monitoring (HR-MRM) based-mass spectrometryJ Proteomics1153648201510.1016/j.jprot.2014.12.002 AassCNorheimIEriksenEFThorsbyPMPepajMSingle unit filter-aided method for fast proteomic analysis of tear fluidAnal Biochem48015201510.1016/j.ab.2015.04.00225862084 ZubarevRAMakarovAOrbitrap mass spectrometryAnal Chem8552885296201310.1021/ac400122323590404 PerryRHCooksRGNollRJOrbitrap mass spectrometry: Instrumentation, ion motion and applicationsMass Spectrom Rev27661699200810.1002/mas.2018618683895 DorMEperonSLalivePHGuex-CrosierYHamedaniMSalvisbergCTurckNInvestigation of the global protein content from healthy human tearsExp Eye Res1796474201910.1016/j.exer.2018.10.006 ShamsiFAChenZLiangJLiKAl-RajhiAAChaudhryIALiMWuKAnalysis and comparison of proteomic profiles of tear fluid from human, cow, sheep, and camel eyesInvest Ophthalmol Vis Sci5291569165201110.1167/iovs.11-830122025569 The definition and classification of dry eye disease: Report of the definition and classification subcommittee of the international dry eye WorkShop (2007)Ocul Surf57592200710.1016/S1542-0124(12)70081-217508116 CraigJPNicholsKKAkpekEKCafferyBDuaHSJooCKLiuZNelsonJDNicholsJJTsubotaKStapletonFTFOS DEWS II definition and classification reportOcul Surf15276283201710.1016/j.jtos.2017.05.00828736335 ShimazakiJDefinition and diagnostic criteria of dry eye disease: Historical overview and future directionsInvest Ophthalmol Vis Sci59DES7DES12201810.1167/iovs.17-2347530481800 AbelsonMBOuslerGWIIINallyLAWelchDKrenzerKAlternative reference values for tear film break up time in normal and dry eye populationsAdv Exp Med Biol50611211125200210.1007/978-1-4615-0717-8_157 SenchynaMWaxMBQuantitative assessment of tear production: A review of methods and utility in dry eye drug discoveryJ Ocul Biol Dis Infor116200810.1007/s12177-008-9006-2200726302802411 NicholsKKMitchellGLZadnikKThe repeatability of clinical measurements of dry eyeCornea23272285200410.1097/00003226-200404000-0001015084861 HuangJFZhangYRittenhouseKDPickeringEHMcDowellMTEvaluations of tear protein markers in dry eye disease: Repeatability of measurement and correlation with diseaseInvest Ophthalmol Vis Sci5345564564201210.1167/iovs.11-905422695964 ZhouLBeuermanRWChanCMZhaoSZLiXRYangHTongLLiuSSternMETanDIdentification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomicsJ Proteome Res848894905200910.1021/pr900686s19705875 RyckmanCVandalKRouleauPTalbotMTessierPAProinflammatory activities of S100: Proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesionJ Immunol17032333242200310.4049/jimmunol.170.6.323312626582 DanjoYLeeMHorimotoKHamanoTOcular surface damage and tear lactoferrin in dry eye syndromeActa Ophthalmol (Copenh)72433437199410.1111/j.1755-3768.1994.tb02791.x BreustedtDASchönfeldDLSkerraAComparative ligand-binding analysis of ten human lipocalinsBiochim Biophys Acta1764161173200610.1016/j.bbapap.2005.12.00616461020 TongLZhouLBeuermanRWZhaoSZLiXRAssociation of tear proteins with meibomian gland disease and dry eye symptomsBr J Ophthalmol95848852201110.1136/bjo.2010.185256 FoellDWittkowskiHRenZTurtonJPangGDaebritzJEhrchenJHeidemannJBorodyTRothJClancyRPhagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel diseaseJ Pathol216183192200810.1002/path.239418729068 VersuraPNanniPBavelloniABlalockWLPiazziMRodaACamposECTear proteomics in evaporative dry eye diseaseEye (Lond)2413961402201010.1038/eye.2010.7 FukudaMFullardRJWillcoxMDBaleriola-LucasCBestawrosFSweeneyDHoldenBAFibronectin in the tear filmInvest Ophthalmol Vis Sci3745946719968603852 PerumalNFunkeSPfeifferNGrusFHProteomics analysis of human tears from aqueous-deficient and evaporative dry eye patientsSci Rep629629201610.1038/srep29629274361154951640 LigtenbergAJVeermanECNieuw AmerongenAVMollenhauerJSalivary agglutinin/glycoprotein-340/DMBT1: A single molecule with variable composition and with different functions in infection, inflammation and cancerBiol Chem38812751289200710.1515/BC.2007.15818020944 BoucherYBraudADufourEAgbo-GodeauSBaarounVDescroixVGuinnepainMTUngeheuerMNOttoneCRougeotCOpiorphin levels in fluids of burning mouth syndrome patients: A case-control studyClin Oral Investig2121572164201710.1007/s00784-016-1991-0 PappaAChenCKoutalosYTownsendAJVasiliouVAldh3a1 protects human corneal epithelial cells from ultraviolet- and 4-hydroxy-2-nonenal-induced oxidative damageFree Radic Biol Med3411781189200310.1016/S0891-5849(03)00070-412706498 SoriaJAceraAMerayo-LLovesJDuránJAGonzálezNRodriguezSBistolasNSchumacherSBierFFPeterHTear proteome analysis in ocular surface diseases using label-free LC-MS/MS and multiplexed-microarray biomarker validationSci Rep717478201710.1038/s41598-017-17536-2292340885727318 MessmerEMvon LindenfelsVGarbeAKampikAMatrix metalloproteinase 9 testing in dry eye disease using a commercially available point-of-care immunoassayOphthalmology12323002308201610.1016/j.ophtha.2016.07.02827665213 JonssonRVogelsangPVolchenkovREspinosaAWahren-HerleniusMAppelSThe complexity of Sjogren's syndrome: Novel aspects on pathogenesisImmunol Lett14119201110.1016/j.imlet.2011.06.00721777618 KuoMTFangPCChaoTLChenALaiYHHuangYTTsengCYTear proteomics approach to monitoring sjogren syndrome or dry eye diseaseInt J Mol Sci201932201910.3390/ijms20081932 AqrawiLAGaltungHKVestadBØvstebøRThiedeBRusthenSYoungAGuerreiroEMUtheimTPChenXIdentification of potential saliva and tear biomarkers in primary Sjögren's syndrome, utilising the extraction of extracellular vesicles and proteomics analysisArthritis Res Ther1914201710.1186/s13075-017-1228-x AqrawiLAGaltungHKGuerreiroEMØvstebøRThiedeBUtheimTPChenXUtheimØAPalmØSkarsteinKJensenJLProteomic and histopathological characterisation of sicca subjects and primary Sjögren's syndrome patients reveals promising tear, saliva and extracellular vesicle disease biomarkersArthritis Res Ther21181201910.1186/s13075-019-1961-4 WongTTZhouLLiJTongLZhaoSZLiXRYuSJKohSKBeuermanRWProteomic profiling of inflammatory signaling molecules in the tears of patients on chronic glaucoma medicationInvest Ophthalmol Vis Sci5273857391201110.1167/iovs.10-653221697136 CsőszÉDeákEKallóGCsutakATőzsérJDiabetic retinopathy: Proteomic approaches to help the differential diagnosis and to understand the underlying molecular mechanismsJ Proteomics150351358201710.1016/j.jprot.2016.06.034 CsőszÉBorossPCsutakABertaATóthFPóliskaSTörökZTőzsérJQuantitative analysis of proteins in the tear fluid of patients with diabetic retinopathyJ Proteomics7521962204201210.1016/j.jprot.2012.01.019 ZhouXQuJXieRWangRJiangLZhaoHWenJLuFNormal development of refractive state and ocular dimensions in guinea pigsVision Res4628152823200610.1016/j.visres.2006.01.02716723148 BartalenaLFatourechiVExtrathyroidal manifestations of Graves' disease: A 2014 updateJ Endocrinol Invest37691700201410.1007/s40618-014-0097-224913238 LehmannGMGarcia-BatesTMSmithTJFeldonSEPhippsRPRegulation of lymphocyte function by PPARgamma: Relevance to thyroid eye disease-related inflammationPPAR Res2008895901200810.1155/2008/895901183547312266979 MouritsMPPrummelMFWiersingaWMKoornneefLClinical activity score as a guide in the management of patients with Graves' ophthalmopathyClin Endocrinol (Oxf)47914199710.1046/j.1365-2265.1997.2331047.x TurckNEperonSDe Los Angeles GraciaMObéricAHamédaniMThyroid-associated orbitopathy and biomarkers: Where we are and what we can hope for the futureDis Markers20187010196201810.1155/2018/7010196297361945875031 ChelalaEEl RamiHDiraniAFakhouryHFadlallahAExtensive superior limbic keratoconjunctivitis in Graves' disease: Case report and mini-review of the literatureClin Ophthalmol94674682015257927984362972 MatheisNOkrojekRGrusFHKahalyGJProteomics of tear fluid in thyroid-associated orbitopathyThyroid2210391045201210.1089/thy.2012.011922873942 TorsteinsdóttirIHâkanssonLHällgrenRGudbjörnssonBArvidsonNGVengePSerum lysozyme: A potential marker of monocyte/macrophage activity in rheumatoid arthritisRheumatology (Oxford)3812491254199910.1093/rheumatology/38.12.1249 BarrettAJThe cystatins: Small protein inhibitors of cysteine proteinasesProg Clin Biol Res18010511619853875863 MatheisNGrusFHBreitenfeldMKnychIFunkeSPitzSPontoKAPfeifferNKahalyGJProteomics differentiate between thyroid-associated orbitopathy and dry eye syndromeInvest Ophthalmol Vis Sci5626492656201510.1167/iovs.15-1669925829418 WiesnerJVilcinskasAAntimicrobial peptides: The ancient arm of the human immune systemVirulence1440464201010.4161/viru.1.5.1298321178486 OzyildirimAMWistowGJGaoJWangJDickinsonDPFriersonHFJrLaurieGWThe lacrimal gland transcriptome is an unusually rich source of rare and poorly characterized gene transcriptsInvest Ophthalmol Vis Sci4615721580200510.1167/iovs.04-138015851553 BarkaTAsbellPAvan der NoenHPrasadACystatins in human tear fluidCurr Eye Res102534199110.3109/027136891090076082029847 TurcuAFKumarSNeumannSCoenenMIyerSChiribogaPGershengornMCBahnRSA small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathyJ Clin Endocrinol Metab9821532159201310.1210/jc.2013-1149234826113644605 AassCNorheimIEriksenEFBørnickECThorsbyPMPepajMComparative proteomic analysis of tear fluid in Graves' disease with and without orbitopathyClin Endocrinol (Oxf)85805812201610.1111/cen.13122 McIntoshRSCadeJEAl-AbedMShanmuganathanVGuptaRBhanATighePJDuaHSThe spectrum of antimicrobial peptide expression at the ocular surfaceInvest Ophthalmol Vis Sci4613791385200510.1167/iovs.04-060715790905 WeiYHChenWLHuFRLiaoSLIn vivo confocal microscopy of bulbar conjunctiva in patients with Graves' ophthalmopathyJ Formos Med Assoc114965972201510.1016/j.jfma.2013.10.003 KishaziEDorMEperonSObericAHamedaniMTurckNThyroid-associated orbitopathy and tears: A proteomics studyJ Proteomics170110116201810.1016/j.jprot.2017.09.001 ParaoanLGriersonIMadenBEAnalysis of expressed sequence tags of retinal pigment epithelium: Cystatin C is an abundant transcriptInt J Biochem Cell Biol32417426200010.1016/S1357-2725(99)00143-010762067 YoshidaAHsuLCDaveVRetinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenaseEnzyme46239244199210.1159/0004687941292933 SahuBMaedaARetinol dehydrogenases regulate vitamin A metabolism for visual functionNutrients8746201610.3390/nu81107465133129 WeinrebRNAungTMedeirosFAThe pathophysiology and treatment of glaucoma: A reviewJAMA31119011911201410.1001/jama.2014.3192248256454523637 BourneRRTaylorHRFlaxmanSRKeeffeJLeasherJNaidooKPesudovsKWhiteRAWongTYResnikoffSNumber of people blind or visually impaired by glaucoma worldwide and in world regions 1990-2010: A meta-analysisPLoS One11e0162229201610.1371/journal.pone.0162229 HarwerthRSQuigleyHAVisual field defects and retinal ganglion cell losses in patients with glaucomaArch Ophthalmol124853859200610.1001/archopht.124.6.853167698392265071 RahmaniBTielschJMKatzJGottschJQuigleyHJavittJSommerAThe cause-specific prevalence of visual impairment in an urban population. The baltimore eye surveyOphthalmology10317211726199610.1016/S0161-6420(96)30435-18942862 BraungerBMFuchshoferRTammERThe aqueous humor outflow pathways in glaucoma: A unifying concept of disease mechanisms and causative treatmentEur J Pharm Biopharm95173181201510.1016/j.ejpb.2015.04.02925957840 ElhawyEKamthanGDongCQDaniasJPseudoexfoliation syndrome, a systemic disorder with ocular manifestationsHum Genomics622201210.1186/1479-7364-6-22231579663500235 WeinrebRNLeungCKCrowstonJGMedeirosFAFriedmanDSWiggsJLMartinKRPrimary open-angle glaucomaNat Rev Dis Primers216067201610.1038/nrdp.2016.6727654570 PieragostinoDBucciSAgnifiliLFasanellaVD'AguannoSMastropasquaACiancagliniMMastropasquaLDi IlioCSacchettaPDifferential protein expression in tears of patients with primary open angle and pseudoexfoliative glaucomaMol Biosyst810171028201210.1039/C1MB05357D PieragostinoDAgnifiliLFasanellaVD'AguannoSMastropasquaRDi IlioCSacchettaPUrbaniADel BoccioPShotgun proteomics reveals specific modulated protein patterns in tears of patients with primary open angle glaucoma naïve to therapyMol Biosyst911081116201310.1039/c3mb25463a23580065

Venn diagram of the number of proteins (UniProt reviewed protein) collected with capillary tube or Schirmer strips in Table I. A total of 2,327 unique proteins (1% False Discovery Rate) were reported in tear fluid using mass spectrometry techniques. Of these, 495 and 1,832 unique proteins were identified in tears collected with a capillary tube and Schirmer's strip, respectively.

Omicsbean Gene Ontology analysis of the 435 common tear proteins. (A) The bars indicate the proportion of converted gene represented per 'Biological Process', 'Cell Component' and 'Molecular Function'. (B) Top 10 enriched significant pathways with the percentage of genes under each pathway of the 435 common proteins.

Human tear proteome identification of healthy subjects using various proteomics approaches coupled with mass spectrometry.

A, Capillary tube
First author, year Sample preparation Mass spectrometer(s) Number of protein identification Clinical condition(s) (Refs.)
Li, 2005 SDS-PAGE; In-gel digestion; In-solution digestion LXQ Deca (Thermo Fisher Scientific, Inc.); Reflex III (Bruker Corporation); QSTAR® Pulsar (SCIEX) 54 Open eye, normal subjects (37)
de Souza, 2006 SDS-PAGE; In-solution digestion LTQ-FT (Thermo Fisher Scientific, Inc.); LTQ-Orbitrap (Thermo Fisher Scientific, Inc.) 491 Closed eye, normal subjects (71)
Ananthi, 2011 SDS-PAGE; In-solution digestion MicrOTOF-Q (Bruker Corporation) 54 Reflex tear fluid, normal subjects (n=40; F=20, M=20) (72)
Shamsi, 2011 SDS-PAGE; In-gel digestion Ultraflex III (Bruker Corporation) 182 Normal subjects (age=35±5; n=25; F=10, M=15) (79)
Perumal, 2015 SDS-PAGE; In-gel digestion LTQ Orbitrap XL™ (Thermo Fisher Scientific, Inc.) 78 Based and reflex tears (age between 20-33 years; n=20; F=10, M=10) (50)
B, Schirmer's strip
First author, year Sample preparation Mass spectrometer(s) Number of protein identification Clinical condition(s) (Refs.)
Zhou, 2012 SCX-RPLC; In-solution digestion TripleTOF 5600 System (SCIEX) 1,543 Normal subjects (age=36±14; n=4; F=3, M=1) (15)
Aass, 2015 SCX-RPLC; In-solution digestion LTQ Orbitrap XL™ (Thermo Fisher Scientific, Inc.) 1,526 Normal subjects (n=3) (75)
Tong, 2015 RPLC; In-solution digestion TripleTOF 5600 System (SCIEX) 747 Normal subjects (age=55.5±14.5; n=1,000; F=589; M=611) (74)
Dor, 2019 RPLC; In-solution digestion LTQ Orbitrap Velos Pro (Thermo Fisher Scientific, Inc.) 1,351 Normal subjects (age=37.6±18.6; n=8; F=4, M=4) (78)
C, Capillary tube and Schirmer's strip
First author, year Sample preparation Mass spectrometer(s) Number of protein identification Clinical condition(s) (Refs.)
Green-Church, 2008 SDS-PAGE; SCX-RPLC; In-gel digestion LTQ (Thermo Fisher Scientific, Inc.) Total, 97; Common, 30; Schirmer's strip, 54; Capillary tube, 13 Closed eye, normal subjects (age=35±13; n=8; F=6, M=2) (31)
Nättinen, 2020 RPLC; In-solution digestion TripleTOF 5600+ System (SCIEX) Total, 992; Common, 316; Schirmer's strip, 592; Capillary tube, 88 Normal subjects (n=31) (24)

List of significantly differentiated tear protein abundance by MS-based proteomic analysis in ocular diseases.

A, Capillary tube
First author, year Separation Mass spectrometry Conditions Differentially expressed protein markers, gene name
(Refs.)
Upregulated Downregulated
Versura, 2010 2D SDS-Page Micromass® Q-Tof (Waters Corporation) Evaporative dry eye (age=64.2±22.3; n=90; F=42, M=18) ALB LCN1, LTF, SCGB1D1, SCGB1D2, SCGB2A1 (93)
Csősz, 2012 RPLC ESI-MS/MS (QTRAP 4000, SCIEX) General diabetic retinopathy (average age=61; n=145) Non-proliferative diabetic retinopathy (average age=56) Proliferative diabetic retinopathy (average age=64) IGLC1, LACRT, LCN1, LFT, LYZ, SCGB1D1 CST4APOA1, IGLC1, LACRT, LCN1, LFT, LYZ, PRB4, SCGB1D1, SCGB2A1 (107)
Soria, 2017 RPLC SYNAPT G2-S HDMS System (Waters Corporation) Aqueous deficient dry eye and control (age=54.58±21.55; n=24; F=14, M=10) Meibomian gland diseases and control (age=54.7±11.6; n=12; F=7, M=5) APOD, C3, CP, IGHG1, ORM2, PLA2G2A, S100A6, S100A8, SERPINA1, SLPI, TXN ANXA1, CLU, LPO, ORM1 LPOIGHG1, PLA2G2A, TXN, SERPINA1, SLPI (99)
B, Schirmer's strip
First author, year Separation Mass spectrometry Conditions Differentially expressed protein markers, gene name
(Refs.)
Upregulated Downregulated
Zhou, 2009 Online 2D SCX-RPLC QSTAR-XL qTOF (SCIEX) General dry eye and control (average age=60; n=56; F=43, M=23) ENO1, ORM1, S100A4, S100A8, S100A9, S100A11 LCN1, LTF, LYZ, PIP (87)
Wong, 2011 Online 2D SCX-RPLC QSTAR-XL qTOF (SCIEX) Glaucoma and control (Topical antiglaucoma medications for >1 year; age=72±7; n=18; F=9, M=9) Glaucoma and control (Topical antiglaucoma medications for <1 year) S100A8, S100A9, SCGB2A1, YWHAZSCGB2A1, S100A8 PRR4PRR4, S100A9, YWHAZ (105)
Matheis, 2012 1D-SDS-PAGE Ultraflex MALDI-TOF/TOF (Bruker Corporation) TAO and control [median age=45 (33-74); n=45] CST4, LYZ B2M, PRB4 (114)
Pieragostino, 2012 1D-SDS-PAGE Reflex IV MALDI-TOF (Bruker Corporation) PXG and control (n=5)POAG and control (n=4)POAG vs. PXG TF, S100A4IGHG1, IGHG2, IGHG4CST2, CST4, IGHG2, LACRT, PRR4, SCGB2A1 AZGP1, CST1, CST2, CST4, IGHA1, KRT1, LACRT, LCN1, LYZ, OPRPN, PIP, PRR4, SCGB2A1, ZG16B ANXA1, AZGP1, CST1, CST2, CST4, IGHA1, IGHA2, IGKC, JCHAIN, KRT1, LCN1, LTF, LYZ, PIGR, PIP, PRR4, SCGB2A1 JCHAIN, KRT19, LGALS3, PIGR, PRDX1, S100A4, S100A8 (136)
Pieragostino, 2013 RPLC LTQ Orbitrap (Thermo Fisher Scientific, Inc.) Primary open angle glaucoma and control (age=55.4±14.5; n=9; F=4, M=5) ACTB, ACTG1, ALB, AZGP1, B2M, CST4, HSPB1, IGHA1, IGHA2, IGKC, JCHAIN, LCN1, LTF, LYZ, OPRPN, PIGR, PIP, POTEE, POTEF, POTEI, POTEJ, PRDX1, PRR4, TF, ZG16B (137)
Matheis, 2015 1D-SDS-PAGE Ultraflex MALDI-TOF/TOF (Bruker Corporation) TAO and control [median age=45.5 (17-68); n=30; F=23, M=7]TAO with DE (TAO: DE) and control [median age=51 (31-70); n=30; F=25, M=5] DE and control [median age=54.5 (32-80); n=30; F=23, M=7] TAO and DETAO and TAO:DE TAO:DE and DE MDN1, POTEILEG3, SMCA4 ANXA1, HSPB1, LEG3, S10A8, SMCA4LYSC PROL1, PRP4, S10A8, SMCA4UGDHANXA1, CYTN, HSPB1, LEG3, PROL1, S10A8, SMCA4, UGDH LEG3 CYTN, PROL1, S10A8, SMCA4, UGDH (117)
Aass, 2016 RPLC LTQ Orbitrap (Thermo Fisher Scientific, Inc.) TAO and control [median age=57 (20-77); n=21; F=15, M=6] APOD, AZGP1, CASP14, DCD, DMBT1, GPX3, LACRT, LYZ, MSLN, PLOD2, SLPI, ZG16B CST5, PPL, SCGB2A2 (122)
Perumal, 2016 IDE LTQ Orbitrap (Thermo Fisher Scientific, Inc.) Evaporative dry eye and control (F age=51.8±18.66; M age=52.9±20.45; n=20; F=10, M=10) Aqueous deficient dry eye (F age=49.6±14.74; M age=47.6±15.32; n=20; F=10, M=10) Aqueous deficient and evaporative dry eye (F age=58.78±17.42; M age (57.73±19.38; n=20; F=10, M=10) S100A8, S100A9ENO1, ORM1, PEBP1, S100A8, S100A9, TFALDH3A1, ENO1, ORM1, PEBP1, S100A8, S100A9, TF PROL1, PRR4, ZG16B DMBT1, PROL1, PRR4, SCGB2A1, ZG16B DMBT1, LACRT, PROL1, PRR4, SCGB2A1, ZG16B (95)
Kishazi, 2018 1D-SDS-PAGE LTQ Orbitrap (Thermo Fisher Scientific, Inc.) TAO and control (age=46.92±11.25; n=28; F=21, M=7) CST3, HP, NQO1, SERPINA3, TXNDC5 ABHD14B, ADH5, ALDH1A1, PLA2G2A, STAT1 (125)

TAO, thyroid-associated orbitopathy; PXG, pseudoexfoliative glaucoma; POAG, primary open angle glaucoma; DE, dry eye.